Finally, given the emerging evidence that class I and II/III are cross-regulating their downstream cellular processes and cooperating to promote cancer cell proliferation, survival and migration, one underexplored strategy could be to specifically target class I, II and/or III PI3K isoforms through combination therapies (Figure 5). This evidence concerns the gene PIK3CB and cancer.